Author(s): Rakoski MO, Singal AG, Rogers MA, Conjeevaram H
Abstract Share this page
Abstract BACKGROUND: Non-alcoholic fatty liver disease generally has a benign course; however, patients with non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma. Currently, there is a lack of consensus about optimal NASH treatment. AIM: To assess the efficacy of insulin-sensitizing agents on histological and biochemical outcomes in randomized control trials of biopsy-proven NASH. METHODS: Multiple online databases and conference abstracts were searched. Random effects meta-analyses were performed, with assessment for heterogeneity and publication bias. RESULTS: Nine trials were included; five trials using thiazolidinediones (glitazones), three using metformin and one trial using both drugs. There was no publication bias. Compared with controls, glitazones resulted in improved steatosis (WMD = 0.57, 95\% CI 0.36-0.77, P = <0.001), hepatocyte ballooning (WMD = 0.36, 95\% CI 0.24-0.49, P < 0.001) and ALT (WMD = 16.4, 95\% CI 7.7-25.0, P < 0.001), but not inflammation (P = 0.09) or fibrosis (P = 0.11). In patients without diabetes, glitazones significantly improved all histological and biochemical outcomes, most importantly including fibrosis (WMD = 0.29, 95\% CI 0.078-0.51, P = 0.008). Metformin failed to improve any pooled outcome. CONCLUSIONS: Treatment of NASH with glitazones, but not metformin, demonstrates a significant histological and biochemical benefit, especially in patients without diabetes. Additional studies are needed to investigate long-term outcomes of glitazone therapy in patients without diabetes. © 2010 Blackwell Publishing Ltd.
This article was published in Aliment Pharmacol Ther
and referenced in Advances in Pharmacoepidemiology and Drug Safety